Approved Indications: Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control Cardiovascular Risk Reduction: Reduction in major adverse cardiovascular events (MACE)including CV death, non-fatal myocardial infarction, and non-fatal strokein adults with T2DM at elevated cardiovascular risk Mechanism of Action: A GLP-1 receptor agonist, semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon release, and delays gastric emptyingresulting in improved glycemic control and favorable metabolic effects
Biochim Biophys Acta, Lipids Lipid Metab
doi: 10.1186/1743-422X-10-251 81 WestAPKhoury-HanoldWStaronMTalMCPinedaCMLangSMet al
However, the clinical application of these approaches is still in its early stages, and significant gaps remain in our understanding of their feasibility, risks, and challenges
Manufacturers will then owe money back to CMS for the difference between the WAC and the negotiated $245 net price
10.2165/11532980-000000000-00000 164 ScheenA